Cancer Therapy Advisor – Results, from the STARGLO trial presented at EHA2024 by Dr Jeremy Abramson

Cancer Therapy Advisor shared a post on X:

“Glofitamab plus GemOx improved outcomes over rituximab plus GemOx in transplant-ineligible patients with relapsed/refractory DLBCL. These results, from the STARGLO trial, were presented at EHA2024 by Dr Jeremy Abramson from Mass General Cancer Center.”